The US Food and Drug Administration (FDA) has today granted approval to PIC for the gene edit used in its PRRS-resistant pig, determining that the technology is safe and effective.

After a long regulatory process to reach this point, PIC described it as a ‘landmark approval’, as it becomes among the first companies to gain approval for gene editing in commercial livestock in the US.

“We have spent years conducting extensive research, validating our findings and working with the FDA to gain approval,” said Matt Culbertson, PIC’s Chief Operating Officer. “Today marks a major milestone for consumers, farmers and the entire pork industry who have desperately hoped for a solution to PRRS.”